Medicare Enrolled

Dr. Nishith Mewada, M.D.

Critical Care Medicine · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
3409 WORTH ST STE 420, Dallas, TX 75246
2148202346
In practice since 2014 (12 years)
NPI: 1063839405 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Mewada from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mewada? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Mewada

Dr. Nishith Mewada is a critical care medicine specialist in Dallas, TX, with 12 years of NPI registration. Based on federal Medicare data, Dr. Mewada performed 290 Medicare services across 182 unique beneficiaries.

Between the years covered by Open Payments, Dr. Mewada received a total of $589 from 17 pharmaceutical and/or device companies across 23 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Mewada is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice ▲ 290 Medicare services $589 industry payments

Medicare Practice Summary

Medicare Utilization ↗
290
Medicare services
Bottom 33% in TX for critical care medicine
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
182
Unique beneficiaries
$127
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~24 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Critical care, first 30-74 min 138 $167 $950
Hospital follow-up visit, high complexity 88 $93 $268
Hospital follow-up visit, moderate complexity 33 $62 $186
Initial hospital admission, high complexity 20 $136 $517
Irrigation and suction of lung airways to obtain cells using an endoscope 11 $85 $1,020
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$589
Total received (2020-2024)
Avg $118/year across 5 years
Bottom 43% in TX for critical care medicine
17
Companies
23
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$589 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$156
2023
$88
2022
$35
2021
$43
2020
$266

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
United Therapeutics Corporation
$139
Mallinckrodt Hospital Products Inc.
$61
Mylan Specialty L.P.
$45
Merck Sharp & Dohme Corporation
$41
Aroa Biosurgery Incorporated
$35
Boehringer Ingelheim Pharmaceuticals, Inc.
$35
Takeda Pharmaceuticals U.S.A., Inc.
$33
GlaxoSmithKline, LLC.
$30
Shionogi Inc
$30
Philips Electronics North America Corporation
$23
KCI USA, Inc.
$23
CSL Behring
$22
ABBVIE INC.
$17
Janssen Pharmaceuticals, Inc
$16
W. L. Gore & Associates, Inc.
$14
Ceribell, Inc.
$13
Insmed, Inc.
$12
Top 3 companies account for 41.7% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · ALLODERM · ANORO ELLIPTA · Arikayce · Fetroja · GLASSIA · GORE SYNECOR Biomaterial · Kcentra · OFEV · PREVENA · SPIRIVA RESPIMAT · TRELEGY ELLIPTA · TYVASO · XARELTO · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $203 per 100 Medicare services performed
Looking for a critical care medicine specialist in Dallas?
Compare critical care medicines in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse critical care medicines nearby

Geographic Context

Critical care medicines within 10 mi
69
Per 100K population
2.6
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Mewada is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Mewada experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Mewada performed 138 critical care, first 30-74 min services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mewada receive payments from pharmaceutical companies?
Yes. Dr. Mewada received a total of $589 from 17 companies across 23 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mewada's costs compare to other critical care medicines in Dallas?
Dr. Mewada's average Medicare payment per service is $127. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mewada) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Critical Care Medicines in Dallas
Browse critical care medicines in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Critical Care Medicines in TX
Critical care medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Critical Care Medicines in TX
Which TX critical care medicines receive the most from drug and device companies.
By company
United Therapeutics Corporation Payments to Doctors
See all physicians who received payments from United Therapeutics Corporation.
By company
Mallinckrodt Hospital Products Inc. Payments to Doctors
See all physicians who received payments from Mallinckrodt Hospital Products Inc.
By company
Mylan Specialty L.P. Payments to Doctors
See all physicians who received payments from Mylan Specialty L.P.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →